nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—CYP2C8—Tazarotene—psoriasis	0.0687	0.112	CbGbCtD
Lapatinib—CYP3A5—Beclomethasone—psoriasis	0.0664	0.108	CbGbCtD
Lapatinib—CYP2C8—Cholecalciferol—psoriasis	0.0293	0.0477	CbGbCtD
Lapatinib—CYP3A5—Mycophenolate mofetil—psoriasis	0.0264	0.043	CbGbCtD
Lapatinib—CYP2C8—Mycophenolate mofetil—psoriasis	0.0254	0.0414	CbGbCtD
Lapatinib—CYP2C19—Cholecalciferol—psoriasis	0.0246	0.04	CbGbCtD
Lapatinib—CYP3A4—Calcitriol—psoriasis	0.0231	0.0375	CbGbCtD
Lapatinib—CYP3A5—Hydrocortisone—psoriasis	0.0212	0.0345	CbGbCtD
Lapatinib—CYP2C8—Hydrocortisone—psoriasis	0.0204	0.0332	CbGbCtD
Lapatinib—CYP3A5—Cyclosporine—psoriasis	0.02	0.0326	CbGbCtD
Lapatinib—CYP2C8—Cyclosporine—psoriasis	0.0193	0.0313	CbGbCtD
Lapatinib—CYP3A4—Methoxsalen—psoriasis	0.018	0.0292	CbGbCtD
Lapatinib—ABCB1—Mycophenolate mofetil—psoriasis	0.0172	0.028	CbGbCtD
Lapatinib—CYP2C19—Prednisone—psoriasis	0.017	0.0277	CbGbCtD
Lapatinib—CYP2C19—Cyclosporine—psoriasis	0.0162	0.0263	CbGbCtD
Lapatinib—ABCB1—Betamethasone—psoriasis	0.0148	0.024	CbGbCtD
Lapatinib—ABCB1—Prednisolone—psoriasis	0.0146	0.0237	CbGbCtD
Lapatinib—ABCB1—Hydrocortisone—psoriasis	0.0138	0.0225	CbGbCtD
Lapatinib—ABCB1—Prednisone—psoriasis	0.0138	0.0224	CbGbCtD
Lapatinib—CYP3A5—Dexamethasone—psoriasis	0.0132	0.0215	CbGbCtD
Lapatinib—ABCB1—Cyclosporine—psoriasis	0.013	0.0212	CbGbCtD
Lapatinib—CYP2C8—Dexamethasone—psoriasis	0.0127	0.0206	CbGbCtD
Lapatinib—CYP3A4—Cholecalciferol—psoriasis	0.0119	0.0193	CbGbCtD
Lapatinib—CYP2C19—Dexamethasone—psoriasis	0.0106	0.0173	CbGbCtD
Lapatinib—CYP3A4—Mycophenolate mofetil—psoriasis	0.0103	0.0168	CbGbCtD
Lapatinib—CYP3A4—Triamcinolone—psoriasis	0.0103	0.0168	CbGbCtD
Lapatinib—CYP3A4—Betamethasone—psoriasis	0.00885	0.0144	CbGbCtD
Lapatinib—CYP3A4—Prednisolone—psoriasis	0.00873	0.0142	CbGbCtD
Lapatinib—ABCB1—Dexamethasone—psoriasis	0.00859	0.014	CbGbCtD
Lapatinib—CYP3A4—Hydrocortisone—psoriasis	0.00827	0.0135	CbGbCtD
Lapatinib—CYP3A4—Prednisone—psoriasis	0.00824	0.0134	CbGbCtD
Lapatinib—CYP3A4—Cyclosporine—psoriasis	0.00781	0.0127	CbGbCtD
Lapatinib—ABCB1—Methotrexate—psoriasis	0.0069	0.0112	CbGbCtD
Lapatinib—CYP3A4—Dexamethasone—psoriasis	0.00515	0.00837	CbGbCtD
Lapatinib—PIK3C2B—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.00185	0.262	CbGdCrCtD
Lapatinib—ERBB2—Triamcinolone—Clobetasol propionate—psoriasis	0.000345	0.0489	CbGdCrCtD
Lapatinib—ERBB2—Desoximetasone—Clobetasol propionate—psoriasis	0.000327	0.0465	CbGdCrCtD
Lapatinib—ERBB2—Triamcinolone—Beclomethasone—psoriasis	0.000276	0.0392	CbGdCrCtD
Lapatinib—ERBB2—Triamcinolone—Fluocinonide—psoriasis	0.000276	0.0392	CbGdCrCtD
Lapatinib—ERBB2—Triamcinolone—Fluocinolone Acetonide—psoriasis	0.000268	0.0381	CbGdCrCtD
Lapatinib—ERBB2—Desoximetasone—Fluocinonide—psoriasis	0.000262	0.0372	CbGdCrCtD
Lapatinib—ERBB2—Desoximetasone—Beclomethasone—psoriasis	0.000262	0.0372	CbGdCrCtD
Lapatinib—PIK3C2B—Exemestane—Prednisone—psoriasis	0.00026	0.0369	CbGdCrCtD
Lapatinib—ERBB2—Desoximetasone—Fluocinolone Acetonide—psoriasis	0.000255	0.0362	CbGdCrCtD
Lapatinib—PIK3C2B—Exemestane—Prednisolone—psoriasis	0.000254	0.036	CbGdCrCtD
Lapatinib—Decreased appetite—Mycophenolic acid—psoriasis	0.000225	0.00109	CcSEcCtD
Lapatinib—Leukopenia—Mycophenolate mofetil—psoriasis	0.000224	0.00109	CcSEcCtD
Lapatinib—Cough—Cyclosporine—psoriasis	0.000224	0.00109	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000223	0.00108	CcSEcCtD
Lapatinib—Fatigue—Mycophenolic acid—psoriasis	0.000223	0.00108	CcSEcCtD
Lapatinib—Asthenia—Hydroxyurea—psoriasis	0.000221	0.00108	CcSEcCtD
Lapatinib—Constipation—Mycophenolic acid—psoriasis	0.000221	0.00107	CcSEcCtD
Lapatinib—Palpitations—Mycophenolate mofetil—psoriasis	0.000221	0.00107	CcSEcCtD
Lapatinib—Myalgia—Cyclosporine—psoriasis	0.000218	0.00106	CcSEcCtD
Lapatinib—Arthralgia—Cyclosporine—psoriasis	0.000218	0.00106	CcSEcCtD
Lapatinib—Cough—Mycophenolate mofetil—psoriasis	0.000218	0.00106	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000217	0.00105	CcSEcCtD
Lapatinib—ERBB2—Exemestane—Prednisone—psoriasis	0.000214	0.0304	CbGdCrCtD
Lapatinib—Myalgia—Mycophenolate mofetil—psoriasis	0.000213	0.00103	CcSEcCtD
Lapatinib—Arthralgia—Mycophenolate mofetil—psoriasis	0.000213	0.00103	CcSEcCtD
Lapatinib—Neuropathy peripheral—Prednisone—psoriasis	0.000213	0.00103	CcSEcCtD
Lapatinib—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000211	0.00103	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000211	0.00103	CcSEcCtD
Lapatinib—Diarrhoea—Hydroxyurea—psoriasis	0.000211	0.00103	CcSEcCtD
Lapatinib—ERBB2—Exemestane—Prednisolone—psoriasis	0.000209	0.0297	CbGdCrCtD
Lapatinib—Anaphylactic shock—Cyclosporine—psoriasis	0.000209	0.00102	CcSEcCtD
Lapatinib—Infection—Cyclosporine—psoriasis	0.000208	0.00101	CcSEcCtD
Lapatinib—Back pain—Triamcinolone—psoriasis	0.000207	0.00101	CcSEcCtD
Lapatinib—Nervous system disorder—Cyclosporine—psoriasis	0.000205	0.000997	CcSEcCtD
Lapatinib—Abdominal pain—Mycophenolic acid—psoriasis	0.000204	0.000993	CcSEcCtD
Lapatinib—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000204	0.000992	CcSEcCtD
Lapatinib—Skin disorder—Cyclosporine—psoriasis	0.000203	0.000987	CcSEcCtD
Lapatinib—Angiopathy—Dexamethasone—psoriasis	0.000203	0.000986	CcSEcCtD
Lapatinib—Angiopathy—Betamethasone—psoriasis	0.000203	0.000986	CcSEcCtD
Lapatinib—Infection—Mycophenolate mofetil—psoriasis	0.000203	0.000985	CcSEcCtD
Lapatinib—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.0002	0.000973	CcSEcCtD
Lapatinib—Anorexia—Cyclosporine—psoriasis	0.000199	0.000969	CcSEcCtD
Lapatinib—Skin disorder—Mycophenolate mofetil—psoriasis	0.000198	0.000963	CcSEcCtD
Lapatinib—Alopecia—Betamethasone—psoriasis	0.000198	0.00096	CcSEcCtD
Lapatinib—Alopecia—Dexamethasone—psoriasis	0.000198	0.00096	CcSEcCtD
Lapatinib—Vomiting—Hydroxyurea—psoriasis	0.000196	0.000954	CcSEcCtD
Lapatinib—Rash—Hydroxyurea—psoriasis	0.000195	0.000946	CcSEcCtD
Lapatinib—Anorexia—Mycophenolate mofetil—psoriasis	0.000194	0.000945	CcSEcCtD
Lapatinib—Dermatitis—Hydroxyurea—psoriasis	0.000194	0.000945	CcSEcCtD
Lapatinib—Myalgia—Hydrocortisone—psoriasis	0.000194	0.000942	CcSEcCtD
Lapatinib—Headache—Hydroxyurea—psoriasis	0.000193	0.00094	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000193	0.000936	CcSEcCtD
Lapatinib—Connective tissue disorder—Prednisone—psoriasis	0.000191	0.00093	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000191	0.000926	CcSEcCtD
Lapatinib—Anaphylactic shock—Prednisolone—psoriasis	0.00019	0.000925	CcSEcCtD
Lapatinib—Neutropenia—Methotrexate—psoriasis	0.00019	0.000924	CcSEcCtD
Lapatinib—Insomnia—Cyclosporine—psoriasis	0.000189	0.000919	CcSEcCtD
Lapatinib—Cough—Triamcinolone—psoriasis	0.000187	0.00091	CcSEcCtD
Lapatinib—Dyspnoea—Cyclosporine—psoriasis	0.000186	0.000906	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000186	0.000904	CcSEcCtD
Lapatinib—Anaphylactic shock—Hydrocortisone—psoriasis	0.000186	0.000903	CcSEcCtD
Lapatinib—Asthenia—Mycophenolic acid—psoriasis	0.000185	0.000902	CcSEcCtD
Lapatinib—Infection—Hydrocortisone—psoriasis	0.000185	0.000898	CcSEcCtD
Lapatinib—Insomnia—Mycophenolate mofetil—psoriasis	0.000185	0.000897	CcSEcCtD
Lapatinib—Dyspepsia—Cyclosporine—psoriasis	0.000184	0.000895	CcSEcCtD
Lapatinib—Nausea—Hydroxyurea—psoriasis	0.000183	0.000891	CcSEcCtD
Lapatinib—Pruritus—Mycophenolic acid—psoriasis	0.000183	0.000889	CcSEcCtD
Lapatinib—Myalgia—Triamcinolone—psoriasis	0.000183	0.000887	CcSEcCtD
Lapatinib—Nervous system disorder—Hydrocortisone—psoriasis	0.000182	0.000886	CcSEcCtD
Lapatinib—Pneumonia—Methotrexate—psoriasis	0.000182	0.000886	CcSEcCtD
Lapatinib—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000182	0.000884	CcSEcCtD
Lapatinib—Decreased appetite—Cyclosporine—psoriasis	0.000182	0.000884	CcSEcCtD
Lapatinib—Infestation—Methotrexate—psoriasis	0.000181	0.000881	CcSEcCtD
Lapatinib—Infestation NOS—Methotrexate—psoriasis	0.000181	0.000881	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000181	0.000878	CcSEcCtD
Lapatinib—Skin disorder—Hydrocortisone—psoriasis	0.000181	0.000878	CcSEcCtD
Lapatinib—Fatigue—Cyclosporine—psoriasis	0.00018	0.000876	CcSEcCtD
Lapatinib—Dyspepsia—Mycophenolate mofetil—psoriasis	0.00018	0.000873	CcSEcCtD
Lapatinib—Constipation—Cyclosporine—psoriasis	0.000179	0.000869	CcSEcCtD
Lapatinib—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000177	0.000862	CcSEcCtD
Lapatinib—Anorexia—Hydrocortisone—psoriasis	0.000177	0.000861	CcSEcCtD
Lapatinib—Diarrhoea—Mycophenolic acid—psoriasis	0.000177	0.00086	CcSEcCtD
Lapatinib—Stomatitis—Methotrexate—psoriasis	0.000177	0.000859	CcSEcCtD
Lapatinib—Angiopathy—Prednisone—psoriasis	0.000177	0.000858	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000176	0.000856	CcSEcCtD
Lapatinib—Immune system disorder—Prednisone—psoriasis	0.000176	0.000855	CcSEcCtD
Lapatinib—Anaphylactic shock—Triamcinolone—psoriasis	0.000175	0.000851	CcSEcCtD
Lapatinib—Constipation—Mycophenolate mofetil—psoriasis	0.000174	0.000848	CcSEcCtD
Lapatinib—Infection—Triamcinolone—psoriasis	0.000174	0.000845	CcSEcCtD
Lapatinib—Insomnia—Prednisolone—psoriasis	0.000172	0.000837	CcSEcCtD
Lapatinib—Alopecia—Prednisone—psoriasis	0.000172	0.000836	CcSEcCtD
Lapatinib—Hepatobiliary disease—Methotrexate—psoriasis	0.000171	0.000833	CcSEcCtD
Lapatinib—Gastrointestinal pain—Cyclosporine—psoriasis	0.000171	0.000831	CcSEcCtD
Lapatinib—Epistaxis—Methotrexate—psoriasis	0.000171	0.000831	CcSEcCtD
Lapatinib—Mental disorder—Prednisone—psoriasis	0.000171	0.000829	CcSEcCtD
Lapatinib—Malnutrition—Prednisone—psoriasis	0.000169	0.000824	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000169	0.000823	CcSEcCtD
Lapatinib—Insomnia—Hydrocortisone—psoriasis	0.000168	0.000817	CcSEcCtD
Lapatinib—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000167	0.000811	CcSEcCtD
Lapatinib—Myalgia—Betamethasone—psoriasis	0.000166	0.000805	CcSEcCtD
Lapatinib—Myalgia—Dexamethasone—psoriasis	0.000166	0.000805	CcSEcCtD
Lapatinib—Abdominal pain—Cyclosporine—psoriasis	0.000165	0.000804	CcSEcCtD
Lapatinib—Vomiting—Mycophenolic acid—psoriasis	0.000164	0.000799	CcSEcCtD
Lapatinib—Dyspepsia—Hydrocortisone—psoriasis	0.000164	0.000795	CcSEcCtD
Lapatinib—Rash—Mycophenolic acid—psoriasis	0.000163	0.000792	CcSEcCtD
Lapatinib—Dermatitis—Mycophenolic acid—psoriasis	0.000163	0.000792	CcSEcCtD
Lapatinib—Headache—Mycophenolic acid—psoriasis	0.000162	0.000787	CcSEcCtD
Lapatinib—Decreased appetite—Hydrocortisone—psoriasis	0.000162	0.000785	CcSEcCtD
Lapatinib—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000161	0.000784	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.00016	0.00078	CcSEcCtD
Lapatinib—Fatigue—Hydrocortisone—psoriasis	0.00016	0.000779	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000159	0.000775	CcSEcCtD
Lapatinib—Anaphylactic shock—Betamethasone—psoriasis	0.000159	0.000772	CcSEcCtD
Lapatinib—Anaphylactic shock—Dexamethasone—psoriasis	0.000159	0.000772	CcSEcCtD
Lapatinib—Insomnia—Triamcinolone—psoriasis	0.000158	0.000769	CcSEcCtD
Lapatinib—Infection—Betamethasone—psoriasis	0.000158	0.000767	CcSEcCtD
Lapatinib—Infection—Dexamethasone—psoriasis	0.000158	0.000767	CcSEcCtD
Lapatinib—Anaemia—Prednisone—psoriasis	0.000157	0.000761	CcSEcCtD
Lapatinib—Dyspnoea—Triamcinolone—psoriasis	0.000156	0.000758	CcSEcCtD
Lapatinib—Nervous system disorder—Betamethasone—psoriasis	0.000156	0.000757	CcSEcCtD
Lapatinib—Nervous system disorder—Dexamethasone—psoriasis	0.000156	0.000757	CcSEcCtD
Lapatinib—Hypersensitivity—Cyclosporine—psoriasis	0.000154	0.000749	CcSEcCtD
Lapatinib—Dyspepsia—Triamcinolone—psoriasis	0.000154	0.000749	CcSEcCtD
Lapatinib—Nausea—Mycophenolic acid—psoriasis	0.000154	0.000746	CcSEcCtD
Lapatinib—PIK3C2B—Testosterone Propionate—Hydrocortisone—psoriasis	0.000153	0.0217	CbGdCrCtD
Lapatinib—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000152	0.000739	CcSEcCtD
Lapatinib—Anorexia—Betamethasone—psoriasis	0.000151	0.000736	CcSEcCtD
Lapatinib—Anorexia—Dexamethasone—psoriasis	0.000151	0.000736	CcSEcCtD
Lapatinib—Cardiac disorder—Methotrexate—psoriasis	0.000151	0.000734	CcSEcCtD
Lapatinib—Fatigue—Triamcinolone—psoriasis	0.000151	0.000733	CcSEcCtD
Lapatinib—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.00015	0.000731	CcSEcCtD
Lapatinib—Asthenia—Cyclosporine—psoriasis	0.00015	0.000729	CcSEcCtD
Lapatinib—Pruritus—Cyclosporine—psoriasis	0.000148	0.000719	CcSEcCtD
Lapatinib—Angiopathy—Methotrexate—psoriasis	0.000148	0.000717	CcSEcCtD
Lapatinib—Immune system disorder—Methotrexate—psoriasis	0.000147	0.000714	CcSEcCtD
Lapatinib—Abdominal pain—Hydrocortisone—psoriasis	0.000147	0.000714	CcSEcCtD
Lapatinib—Mediastinal disorder—Methotrexate—psoriasis	0.000147	0.000713	CcSEcCtD
Lapatinib—Asthenia—Mycophenolate mofetil—psoriasis	0.000146	0.000712	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000145	0.000703	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000145	0.000703	CcSEcCtD
Lapatinib—Pruritus—Mycophenolate mofetil—psoriasis	0.000144	0.000702	CcSEcCtD
Lapatinib—Myalgia—Prednisone—psoriasis	0.000144	0.000701	CcSEcCtD
Lapatinib—Arthralgia—Prednisone—psoriasis	0.000144	0.000701	CcSEcCtD
Lapatinib—Alopecia—Methotrexate—psoriasis	0.000144	0.000699	CcSEcCtD
Lapatinib—Insomnia—Dexamethasone—psoriasis	0.000144	0.000698	CcSEcCtD
Lapatinib—Insomnia—Betamethasone—psoriasis	0.000144	0.000698	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000143	0.000696	CcSEcCtD
Lapatinib—Diarrhoea—Cyclosporine—psoriasis	0.000143	0.000696	CcSEcCtD
Lapatinib—Mental disorder—Methotrexate—psoriasis	0.000143	0.000693	CcSEcCtD
Lapatinib—Malnutrition—Methotrexate—psoriasis	0.000142	0.000688	CcSEcCtD
Lapatinib—Hypersensitivity—Prednisolone—psoriasis	0.00014	0.000682	CcSEcCtD
Lapatinib—Dyspepsia—Betamethasone—psoriasis	0.00014	0.000679	CcSEcCtD
Lapatinib—Dyspepsia—Dexamethasone—psoriasis	0.00014	0.000679	CcSEcCtD
Lapatinib—Diarrhoea—Mycophenolate mofetil—psoriasis	0.00014	0.000679	CcSEcCtD
Lapatinib—Anaphylactic shock—Prednisone—psoriasis	0.000138	0.000672	CcSEcCtD
Lapatinib—Decreased appetite—Betamethasone—psoriasis	0.000138	0.000671	CcSEcCtD
Lapatinib—Decreased appetite—Dexamethasone—psoriasis	0.000138	0.000671	CcSEcCtD
Lapatinib—Infection—Prednisone—psoriasis	0.000137	0.000668	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000137	0.000666	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Betamethasone—psoriasis	0.000137	0.000666	CcSEcCtD
Lapatinib—Back pain—Methotrexate—psoriasis	0.000137	0.000666	CcSEcCtD
Lapatinib—Hypersensitivity—Hydrocortisone—psoriasis	0.000137	0.000666	CcSEcCtD
Lapatinib—Fatigue—Dexamethasone—psoriasis	0.000137	0.000666	CcSEcCtD
Lapatinib—Fatigue—Betamethasone—psoriasis	0.000137	0.000666	CcSEcCtD
Lapatinib—Nervous system disorder—Prednisone—psoriasis	0.000136	0.000659	CcSEcCtD
Lapatinib—ERBB2—Triamcinolone—Hydrocortisone—psoriasis	0.000136	0.0192	CbGdCrCtD
Lapatinib—Skin disorder—Prednisone—psoriasis	0.000134	0.000653	CcSEcCtD
Lapatinib—Asthenia—Hydrocortisone—psoriasis	0.000133	0.000648	CcSEcCtD
Lapatinib—Vomiting—Cyclosporine—psoriasis	0.000133	0.000646	CcSEcCtD
Lapatinib—Rash—Cyclosporine—psoriasis	0.000132	0.000641	CcSEcCtD
Lapatinib—Anorexia—Prednisone—psoriasis	0.000132	0.000641	CcSEcCtD
Lapatinib—Dermatitis—Cyclosporine—psoriasis	0.000132	0.00064	CcSEcCtD
Lapatinib—Pruritus—Hydrocortisone—psoriasis	0.000132	0.000639	CcSEcCtD
Lapatinib—Headache—Cyclosporine—psoriasis	0.000131	0.000637	CcSEcCtD
Lapatinib—Anaemia—Methotrexate—psoriasis	0.000131	0.000636	CcSEcCtD
Lapatinib—Gastrointestinal pain—Dexamethasone—psoriasis	0.00013	0.000631	CcSEcCtD
Lapatinib—Gastrointestinal pain—Betamethasone—psoriasis	0.00013	0.000631	CcSEcCtD
Lapatinib—Vomiting—Mycophenolate mofetil—psoriasis	0.00013	0.000631	CcSEcCtD
Lapatinib—Hypersensitivity—Triamcinolone—psoriasis	0.000129	0.000627	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Hydrocortisone—psoriasis	0.000129	0.0183	CbGdCrCtD
Lapatinib—Rash—Mycophenolate mofetil—psoriasis	0.000129	0.000625	CcSEcCtD
Lapatinib—Dermatitis—Mycophenolate mofetil—psoriasis	0.000129	0.000625	CcSEcCtD
Lapatinib—Headache—Mycophenolate mofetil—psoriasis	0.000128	0.000621	CcSEcCtD
Lapatinib—PIK3C2B—Danazol—Hydrocortisone—psoriasis	0.000127	0.0181	CbGdCrCtD
Lapatinib—Diarrhoea—Hydrocortisone—psoriasis	0.000127	0.000618	CcSEcCtD
Lapatinib—Leukopenia—Methotrexate—psoriasis	0.000127	0.000616	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Prednisone—psoriasis	0.000126	0.000612	CcSEcCtD
Lapatinib—ERBB2—Triamcinolone—Betamethasone—psoriasis	0.000126	0.0179	CbGdCrCtD
Lapatinib—ERBB2—Triamcinolone—Dexamethasone—psoriasis	0.000126	0.0179	CbGdCrCtD
Lapatinib—Asthenia—Triamcinolone—psoriasis	0.000126	0.00061	CcSEcCtD
Lapatinib—Abdominal pain—Betamethasone—psoriasis	0.000126	0.00061	CcSEcCtD
Lapatinib—Abdominal pain—Dexamethasone—psoriasis	0.000126	0.00061	CcSEcCtD
Lapatinib—Insomnia—Prednisone—psoriasis	0.000125	0.000608	CcSEcCtD
Lapatinib—Nausea—Cyclosporine—psoriasis	0.000124	0.000604	CcSEcCtD
Lapatinib—Pruritus—Triamcinolone—psoriasis	0.000124	0.000602	CcSEcCtD
Lapatinib—Cough—Methotrexate—psoriasis	0.000124	0.000601	CcSEcCtD
Lapatinib—Dyspepsia—Prednisone—psoriasis	0.000122	0.000592	CcSEcCtD
Lapatinib—Nausea—Mycophenolate mofetil—psoriasis	0.000121	0.000589	CcSEcCtD
Lapatinib—Arthralgia—Methotrexate—psoriasis	0.000121	0.000586	CcSEcCtD
Lapatinib—Myalgia—Methotrexate—psoriasis	0.000121	0.000586	CcSEcCtD
Lapatinib—Decreased appetite—Prednisone—psoriasis	0.00012	0.000584	CcSEcCtD
Lapatinib—Rash—Prednisolone—psoriasis	0.00012	0.000583	CcSEcCtD
Lapatinib—Dermatitis—Prednisolone—psoriasis	0.00012	0.000583	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.00012	0.000582	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Betamethasone—psoriasis	0.00012	0.017	CbGdCrCtD
Lapatinib—ERBB2—Desoximetasone—Dexamethasone—psoriasis	0.00012	0.017	CbGdCrCtD
Lapatinib—Fatigue—Prednisone—psoriasis	0.000119	0.00058	CcSEcCtD
Lapatinib—Headache—Prednisolone—psoriasis	0.000119	0.00058	CcSEcCtD
Lapatinib—Constipation—Prednisone—psoriasis	0.000118	0.000575	CcSEcCtD
Lapatinib—Vomiting—Hydrocortisone—psoriasis	0.000118	0.000574	CcSEcCtD
Lapatinib—Rash—Hydrocortisone—psoriasis	0.000117	0.00057	CcSEcCtD
Lapatinib—Dermatitis—Hydrocortisone—psoriasis	0.000117	0.000569	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Triamcinolone—psoriasis	0.000117	0.0166	CbGdCrCtD
Lapatinib—ERBB2—Triamcinolone—Prednisone—psoriasis	0.000117	0.0166	CbGdCrCtD
Lapatinib—Headache—Hydrocortisone—psoriasis	0.000116	0.000566	CcSEcCtD
Lapatinib—Anaphylactic shock—Methotrexate—psoriasis	0.000116	0.000562	CcSEcCtD
Lapatinib—PIK3C2B—Norethindrone—Hydrocortisone—psoriasis	0.000115	0.0163	CbGdCrCtD
Lapatinib—Infection—Methotrexate—psoriasis	0.000115	0.000558	CcSEcCtD
Lapatinib—ERBB2—Triamcinolone—Prednisolone—psoriasis	0.000114	0.0162	CbGdCrCtD
Lapatinib—Asthenia—Dexamethasone—psoriasis	0.000114	0.000554	CcSEcCtD
Lapatinib—Asthenia—Betamethasone—psoriasis	0.000114	0.000554	CcSEcCtD
Lapatinib—Nervous system disorder—Methotrexate—psoriasis	0.000113	0.000551	CcSEcCtD
Lapatinib—Gastrointestinal pain—Prednisone—psoriasis	0.000113	0.00055	CcSEcCtD
Lapatinib—Nausea—Prednisolone—psoriasis	0.000113	0.000549	CcSEcCtD
Lapatinib—Pruritus—Dexamethasone—psoriasis	0.000112	0.000546	CcSEcCtD
Lapatinib—Pruritus—Betamethasone—psoriasis	0.000112	0.000546	CcSEcCtD
Lapatinib—Skin disorder—Methotrexate—psoriasis	0.000112	0.000546	CcSEcCtD
Lapatinib—Vomiting—Triamcinolone—psoriasis	0.000111	0.000541	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Prednisone—psoriasis	0.000111	0.0157	CbGdCrCtD
Lapatinib—Nausea—Hydrocortisone—psoriasis	0.00011	0.000537	CcSEcCtD
Lapatinib—Rash—Triamcinolone—psoriasis	0.00011	0.000536	CcSEcCtD
Lapatinib—Dermatitis—Triamcinolone—psoriasis	0.00011	0.000536	CcSEcCtD
Lapatinib—Anorexia—Methotrexate—psoriasis	0.00011	0.000536	CcSEcCtD
Lapatinib—PIK3C2B—Danazol—Prednisone—psoriasis	0.00011	0.0156	CbGdCrCtD
Lapatinib—Headache—Triamcinolone—psoriasis	0.00011	0.000533	CcSEcCtD
Lapatinib—Abdominal pain—Prednisone—psoriasis	0.000109	0.000531	CcSEcCtD
Lapatinib—Diarrhoea—Dexamethasone—psoriasis	0.000109	0.000528	CcSEcCtD
Lapatinib—Diarrhoea—Betamethasone—psoriasis	0.000109	0.000528	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Prednisolone—psoriasis	0.000108	0.0153	CbGdCrCtD
Lapatinib—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000105	0.000512	CcSEcCtD
Lapatinib—Insomnia—Methotrexate—psoriasis	0.000105	0.000508	CcSEcCtD
Lapatinib—Nausea—Triamcinolone—psoriasis	0.000104	0.000505	CcSEcCtD
Lapatinib—Dyspnoea—Methotrexate—psoriasis	0.000103	0.000501	CcSEcCtD
Lapatinib—Hypersensitivity—Prednisone—psoriasis	0.000102	0.000495	CcSEcCtD
Lapatinib—Dyspepsia—Methotrexate—psoriasis	0.000102	0.000495	CcSEcCtD
Lapatinib—Vomiting—Betamethasone—psoriasis	0.000101	0.000491	CcSEcCtD
Lapatinib—Vomiting—Dexamethasone—psoriasis	0.000101	0.000491	CcSEcCtD
Lapatinib—Decreased appetite—Methotrexate—psoriasis	0.0001	0.000488	CcSEcCtD
Lapatinib—Rash—Betamethasone—psoriasis	0.0001	0.000487	CcSEcCtD
Lapatinib—Rash—Dexamethasone—psoriasis	0.0001	0.000487	CcSEcCtD
Lapatinib—Dermatitis—Dexamethasone—psoriasis	0.0001	0.000486	CcSEcCtD
Lapatinib—Dermatitis—Betamethasone—psoriasis	0.0001	0.000486	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Methotrexate—psoriasis	9.98e-05	0.000485	CcSEcCtD
Lapatinib—Fatigue—Methotrexate—psoriasis	9.96e-05	0.000484	CcSEcCtD
Lapatinib—Headache—Dexamethasone—psoriasis	9.95e-05	0.000484	CcSEcCtD
Lapatinib—Headache—Betamethasone—psoriasis	9.95e-05	0.000484	CcSEcCtD
Lapatinib—Asthenia—Prednisone—psoriasis	9.92e-05	0.000482	CcSEcCtD
Lapatinib—Pruritus—Prednisone—psoriasis	9.78e-05	0.000476	CcSEcCtD
Lapatinib—Diarrhoea—Prednisone—psoriasis	9.46e-05	0.00046	CcSEcCtD
Lapatinib—Gastrointestinal pain—Methotrexate—psoriasis	9.45e-05	0.000459	CcSEcCtD
Lapatinib—Nausea—Dexamethasone—psoriasis	9.43e-05	0.000459	CcSEcCtD
Lapatinib—Nausea—Betamethasone—psoriasis	9.43e-05	0.000459	CcSEcCtD
Lapatinib—PIK3C2B—Levonorgestrel—Hydrocortisone—psoriasis	9.14e-05	0.013	CbGdCrCtD
Lapatinib—Abdominal pain—Methotrexate—psoriasis	9.14e-05	0.000444	CcSEcCtD
Lapatinib—Vomiting—Prednisone—psoriasis	8.79e-05	0.000427	CcSEcCtD
Lapatinib—Rash—Prednisone—psoriasis	8.72e-05	0.000424	CcSEcCtD
Lapatinib—Dermatitis—Prednisone—psoriasis	8.71e-05	0.000423	CcSEcCtD
Lapatinib—Headache—Prednisone—psoriasis	8.66e-05	0.000421	CcSEcCtD
Lapatinib—Hypersensitivity—Methotrexate—psoriasis	8.52e-05	0.000414	CcSEcCtD
Lapatinib—Asthenia—Methotrexate—psoriasis	8.29e-05	0.000403	CcSEcCtD
Lapatinib—Nausea—Prednisone—psoriasis	8.21e-05	0.000399	CcSEcCtD
Lapatinib—Pruritus—Methotrexate—psoriasis	8.18e-05	0.000397	CcSEcCtD
Lapatinib—Diarrhoea—Methotrexate—psoriasis	7.91e-05	0.000384	CcSEcCtD
Lapatinib—ERBB2—Levonorgestrel—Hydrocortisone—psoriasis	7.53e-05	0.0107	CbGdCrCtD
Lapatinib—Vomiting—Methotrexate—psoriasis	7.35e-05	0.000357	CcSEcCtD
Lapatinib—Rash—Methotrexate—psoriasis	7.29e-05	0.000354	CcSEcCtD
Lapatinib—Dermatitis—Methotrexate—psoriasis	7.28e-05	0.000354	CcSEcCtD
Lapatinib—Headache—Methotrexate—psoriasis	7.24e-05	0.000352	CcSEcCtD
Lapatinib—Nausea—Methotrexate—psoriasis	6.87e-05	0.000334	CcSEcCtD
Lapatinib—EGFR—Adaptive Immune System—HLA-E—psoriasis	5.31e-05	0.000308	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—TYK2—psoriasis	5.3e-05	0.000307	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TAGAP—psoriasis	5.28e-05	0.000306	CbGpPWpGaD
Lapatinib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	5.26e-05	0.000305	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	5.22e-05	0.000303	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—NDUFA5—psoriasis	5.18e-05	0.0003	CbGpPWpGaD
Lapatinib—EGFR—Focal Adhesion—JUN—psoriasis	5.12e-05	0.000297	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	5.1e-05	0.000296	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—STAT3—psoriasis	5.06e-05	0.000293	CbGpPWpGaD
Lapatinib—EGFR—EGF/EGFR Signaling Pathway—STAT3—psoriasis	5.04e-05	0.000292	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—TP53—psoriasis	4.95e-05	0.000287	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CD8A—psoriasis	4.94e-05	0.000286	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	4.91e-05	0.000285	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—CD4—psoriasis	4.87e-05	0.000282	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CD8A—psoriasis	4.86e-05	0.000282	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—NFKB1—psoriasis	4.83e-05	0.00028	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—CD4—psoriasis	4.8e-05	0.000278	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—NFKB1—psoriasis	4.75e-05	0.000275	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—HLA-B—psoriasis	4.75e-05	0.000275	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—STAT3—psoriasis	4.69e-05	0.000272	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—HLA-B—psoriasis	4.68e-05	0.000271	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—CD4—psoriasis	4.68e-05	0.000271	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	4.62e-05	0.000268	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—SOCS1—psoriasis	4.62e-05	0.000268	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by NGF—IL6—psoriasis	4.62e-05	0.000268	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—CD4—psoriasis	4.61e-05	0.000267	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—STAT3—psoriasis	4.59e-05	0.000266	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—TYK2—psoriasis	4.56e-05	0.000265	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—VEGFA—psoriasis	4.56e-05	0.000264	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by NGF—IL6—psoriasis	4.55e-05	0.000264	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—IL6—psoriasis	4.53e-05	0.000263	CbGpPWpGaD
Lapatinib—EGFR—Immune System—ITGAL—psoriasis	4.51e-05	0.000262	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—NDUFA5—psoriasis	4.48e-05	0.00026	CbGpPWpGaD
Lapatinib—EGFR—Focal Adhesion—VEGFA—psoriasis	4.48e-05	0.00026	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	4.46e-05	0.000258	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—SOCS1—psoriasis	4.44e-05	0.000257	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CYP2S1—psoriasis	4.4e-05	0.000255	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—HLA-A—psoriasis	4.4e-05	0.000255	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—JUN—psoriasis	4.36e-05	0.000253	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—HLA-A—psoriasis	4.34e-05	0.000251	CbGpPWpGaD
Lapatinib—EGFR—Direct p53 effectors—TP53—psoriasis	4.32e-05	0.00025	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—VEGFA—psoriasis	4.31e-05	0.00025	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—JUN—psoriasis	4.29e-05	0.000249	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—STAT3—psoriasis	4.27e-05	0.000247	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—TNF—psoriasis	4.23e-05	0.000245	CbGpPWpGaD
Lapatinib—EGFR—Immune System—REL—psoriasis	4.22e-05	0.000245	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CRP—psoriasis	4.2e-05	0.000243	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—NFKB1—psoriasis	4.2e-05	0.000243	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.18e-05	0.000242	CbGpPWpGaD
Lapatinib—ERBB2—Axon guidance—IL6—psoriasis	4.18e-05	0.000242	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	4.15e-05	0.000241	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CRP—psoriasis	4.14e-05	0.00024	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—NFKB1—psoriasis	4.13e-05	0.00024	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—TYK2—psoriasis	4.13e-05	0.000239	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IFIH1—psoriasis	4.1e-05	0.000237	CbGpPWpGaD
Lapatinib—TAP1—Immune System—IL6—psoriasis	4.08e-05	0.000237	CbGpPWpGaD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—TP53—psoriasis	4.06e-05	0.000236	CbGpPWpGaD
Lapatinib—ERBB2—Disease—HLA-A—psoriasis	4.06e-05	0.000236	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—NFKB1—psoriasis	4.03e-05	0.000234	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—HLA-DRB1—psoriasis	4.02e-05	0.000233	CbGpPWpGaD
Lapatinib—ERBB4—Disease—HLA-A—psoriasis	4e-05	0.000232	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NDUFA5—psoriasis	4e-05	0.000232	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—NFKB1—psoriasis	3.97e-05	0.00023	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—HLA-DRB1—psoriasis	3.96e-05	0.00023	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—HLA-B—psoriasis	3.94e-05	0.000229	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—CD8A—psoriasis	3.94e-05	0.000228	CbGpPWpGaD
Lapatinib—EGFR—Signaling by SCF-KIT—IL6—psoriasis	3.93e-05	0.000228	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—TNF—psoriasis	3.91e-05	0.000227	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NDUFA5—psoriasis	3.91e-05	0.000226	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.88e-05	0.000225	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-C—psoriasis	3.88e-05	0.000225	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—LEP—psoriasis	3.86e-05	0.000224	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—ICAM1—psoriasis	3.86e-05	0.000224	CbGpPWpGaD
Lapatinib—EGFR—Immune System—TNFAIP3—psoriasis	3.84e-05	0.000222	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—NFKBIA—psoriasis	3.83e-05	0.000222	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.82e-05	0.000221	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP2S1—psoriasis	3.81e-05	0.000221	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—ICAM1—psoriasis	3.8e-05	0.00022	CbGpPWpGaD
Lapatinib—ERBB2—Disease—APOE—psoriasis	3.79e-05	0.00022	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HLA-B—psoriasis	3.79e-05	0.000219	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—NFKBIA—psoriasis	3.77e-05	0.000219	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling of activated FGFR—IL6—psoriasis	3.76e-05	0.000218	CbGpPWpGaD
Lapatinib—ERBB4—Disease—APOE—psoriasis	3.74e-05	0.000217	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—TP53—psoriasis	3.73e-05	0.000216	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.73e-05	0.000216	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—IL6—psoriasis	3.7e-05	0.000215	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—TNF—psoriasis	3.69e-05	0.000214	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	3.63e-05	0.00021	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—SOCS1—psoriasis	3.6e-05	0.000209	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—NFKB1—psoriasis	3.56e-05	0.000206	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—SOCS1—psoriasis	3.55e-05	0.000206	CbGpPWpGaD
Lapatinib—ERBB2—Disease—NOS2—psoriasis	3.54e-05	0.000205	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—IL6—psoriasis	3.53e-05	0.000205	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—IL6—psoriasis	3.52e-05	0.000204	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HLA-A—psoriasis	3.51e-05	0.000203	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—IL6—psoriasis	3.5e-05	0.000203	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—CRP—psoriasis	3.48e-05	0.000202	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—IL6—psoriasis	3.48e-05	0.000202	CbGpPWpGaD
Lapatinib—ERBB4—Disease—NOS2—psoriasis	3.48e-05	0.000202	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	3.46e-05	0.000201	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP2S1—psoriasis	3.4e-05	0.000197	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.37e-05	0.000195	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—PPARG—psoriasis	3.36e-05	0.000195	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP2S1—psoriasis	3.32e-05	0.000193	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—IL6—psoriasis	3.28e-05	0.00019	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	3.28e-05	0.00019	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—IL6—psoriasis	3.28e-05	0.00019	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—IL6—psoriasis	3.25e-05	0.000188	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-E—psoriasis	3.22e-05	0.000187	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—IL6—psoriasis	3.22e-05	0.000187	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HLA-DRB1—psoriasis	3.2e-05	0.000186	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—IL6—psoriasis	3.2e-05	0.000186	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—STAT3—psoriasis	3.2e-05	0.000185	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—NFKBIA—psoriasis	3.18e-05	0.000184	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCL20—psoriasis	3.16e-05	0.000183	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—TYK2—psoriasis	3.14e-05	0.000182	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—TYK2—psoriasis	3.09e-05	0.000179	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—ICAM1—psoriasis	3.08e-05	0.000178	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—NFKBIA—psoriasis	3.05e-05	0.000177	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—IL6—psoriasis	2.98e-05	0.000173	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—TYK2—psoriasis	2.95e-05	0.000171	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IFNG—psoriasis	2.94e-05	0.00017	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—VEGFA—psoriasis	2.92e-05	0.000169	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	2.9e-05	0.000168	CbGpPWpGaD
Lapatinib—ERBB2—Disease—TYK2—psoriasis	2.9e-05	0.000168	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IFNG—psoriasis	2.89e-05	0.000168	CbGpPWpGaD
Lapatinib—ERBB4—Disease—TYK2—psoriasis	2.85e-05	0.000165	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CD4—psoriasis	2.84e-05	0.000164	CbGpPWpGaD
Lapatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.8e-05	0.000163	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CD4—psoriasis	2.79e-05	0.000162	CbGpPWpGaD
Lapatinib—EGFR—Immune System—SOCS1—psoriasis	2.69e-05	0.000156	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—LEP—psoriasis	2.66e-05	0.000154	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—APOE—psoriasis	2.66e-05	0.000154	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—IL6—psoriasis	2.63e-05	0.000153	CbGpPWpGaD
Lapatinib—ERBB2—Disease—CD4—psoriasis	2.62e-05	0.000152	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—APOE—psoriasis	2.62e-05	0.000152	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—LEP—psoriasis	2.62e-05	0.000152	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—TYK2—psoriasis	2.6e-05	0.000151	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—IL6—psoriasis	2.59e-05	0.00015	CbGpPWpGaD
Lapatinib—ERBB4—Disease—CD4—psoriasis	2.58e-05	0.00015	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.58e-05	0.000149	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—JUN—psoriasis	2.54e-05	0.000147	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—JUN—psoriasis	2.5e-05	0.000145	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.48e-05	0.000144	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NFKBIA—psoriasis	2.48e-05	0.000144	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—NFKB1—psoriasis	2.44e-05	0.000142	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NFKBIA—psoriasis	2.44e-05	0.000141	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—NFKB1—psoriasis	2.41e-05	0.00014	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NDUFA5—psoriasis	2.41e-05	0.00014	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD8A—psoriasis	2.39e-05	0.000138	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—CD4—psoriasis	2.35e-05	0.000136	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—NFKB1—psoriasis	2.3e-05	0.000133	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-B—psoriasis	2.3e-05	0.000133	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—CD4—psoriasis	2.26e-05	0.000131	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.25e-05	0.00013	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—IL6—psoriasis	2.23e-05	0.000129	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—STAT3—psoriasis	2.2e-05	0.000127	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—STAT3—psoriasis	2.16e-05	0.000125	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CARM1—psoriasis	2.15e-05	0.000125	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-A—psoriasis	2.13e-05	0.000123	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—JUN—psoriasis	2.11e-05	0.000122	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—VEGFA—psoriasis	2.08e-05	0.000121	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—STAT3—psoriasis	2.06e-05	0.00012	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP2S1—psoriasis	2.05e-05	0.000119	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CRP—psoriasis	2.03e-05	0.000118	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—NFKB1—psoriasis	2.03e-05	0.000118	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TYK2—psoriasis	2.03e-05	0.000118	CbGpPWpGaD
Lapatinib—ERBB2—Disease—STAT3—psoriasis	2.03e-05	0.000118	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—IL6—psoriasis	2.02e-05	0.000117	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	2e-05	0.000116	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TYK2—psoriasis	2e-05	0.000116	CbGpPWpGaD
Lapatinib—ERBB4—Disease—STAT3—psoriasis	2e-05	0.000116	CbGpPWpGaD
Lapatinib—EGFR—Disease—HLA-A—psoriasis	1.96e-05	0.000114	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—NFKB1—psoriasis	1.95e-05	0.000113	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-DRB1—psoriasis	1.94e-05	0.000113	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.93e-05	0.000112	CbGpPWpGaD
Lapatinib—EGFR—Immune System—ICAM1—psoriasis	1.87e-05	0.000108	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CARM1—psoriasis	1.86e-05	0.000108	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NFKBIA—psoriasis	1.85e-05	0.000107	CbGpPWpGaD
Lapatinib—EGFR—Disease—APOE—psoriasis	1.83e-05	0.000106	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—TNF—psoriasis	1.79e-05	0.000104	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.78e-05	0.000103	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CXCL8—psoriasis	1.77e-05	0.000102	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.74e-05	0.000101	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SOCS1—psoriasis	1.74e-05	0.000101	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CXCL8—psoriasis	1.74e-05	0.000101	CbGpPWpGaD
Lapatinib—EGFR—Disease—NOS2—psoriasis	1.71e-05	9.91e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.7e-05	9.86e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CARM1—psoriasis	1.66e-05	9.64e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—TYK2—psoriasis	1.66e-05	9.62e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—JUN—psoriasis	1.64e-05	9.51e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CARM1—psoriasis	1.62e-05	9.4e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—JUN—psoriasis	1.62e-05	9.37e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NFKB1—psoriasis	1.58e-05	9.16e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NFKB1—psoriasis	1.56e-05	9.02e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.55e-05	9.01e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IL6—psoriasis	1.53e-05	8.89e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—TYK2—psoriasis	1.52e-05	8.79e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IL6—psoriasis	1.51e-05	8.76e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CXCL8—psoriasis	1.44e-05	8.38e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—IL6—psoriasis	1.44e-05	8.36e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—VEGFA—psoriasis	1.43e-05	8.31e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—STAT3—psoriasis	1.42e-05	8.23e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IFNG—psoriasis	1.42e-05	8.23e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—IL6—psoriasis	1.42e-05	8.21e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—VEGFA—psoriasis	1.41e-05	8.19e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—TYK2—psoriasis	1.4e-05	8.12e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—STAT3—psoriasis	1.4e-05	8.11e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—IL6—psoriasis	1.39e-05	8.09e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD4—psoriasis	1.37e-05	7.95e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CAT—psoriasis	1.32e-05	7.67e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—APOE—psoriasis	1.28e-05	7.45e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—LEP—psoriasis	1.28e-05	7.45e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—IL6—psoriasis	1.27e-05	7.38e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CD4—psoriasis	1.27e-05	7.34e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—JUN—psoriasis	1.23e-05	7.11e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NFKBIA—psoriasis	1.2e-05	6.94e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NFKB1—psoriasis	1.18e-05	6.85e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CAT—psoriasis	1.15e-05	6.64e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TP53—psoriasis	1.08e-05	6.28e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TP53—psoriasis	1.07e-05	6.19e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—STAT3—psoriasis	1.06e-05	6.15e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—APOE—psoriasis	1.03e-05	5.96e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CAT—psoriasis	1.02e-05	5.93e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CARM1—psoriasis	9.99e-06	5.79e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CAT—psoriasis	9.98e-06	5.78e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL6—psoriasis	9.92e-06	5.75e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TYK2—psoriasis	9.8e-06	5.68e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—STAT3—psoriasis	9.8e-06	5.68e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL6—psoriasis	9.77e-06	5.66e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PPARG—psoriasis	8.95e-06	5.19e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—APOE—psoriasis	8.9e-06	5.16e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CXCL8—psoriasis	8.53e-06	4.95e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL6—psoriasis	8.12e-06	4.7e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—APOE—psoriasis	7.94e-06	4.6e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—JUN—psoriasis	7.93e-06	4.6e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—APOE—psoriasis	7.75e-06	4.49e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PPARG—psoriasis	7.75e-06	4.49e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NFKB1—psoriasis	7.64e-06	4.43e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL6—psoriasis	7.41e-06	4.3e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—VEGFA—psoriasis	6.93e-06	4.02e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PPARG—psoriasis	6.92e-06	4.01e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—STAT3—psoriasis	6.86e-06	3.98e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—IL6—psoriasis	6.85e-06	3.97e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PPARG—psoriasis	6.75e-06	3.91e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CAT—psoriasis	6.15e-06	3.56e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TP53—psoriasis	5.24e-06	3.04e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL6—psoriasis	4.79e-06	2.78e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—APOE—psoriasis	4.78e-06	2.77e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PPARG—psoriasis	4.16e-06	2.41e-05	CbGpPWpGaD
